These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34278611)

  • 21. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial.
    Crawford BA; Kam C; Pavlovic J; Byth K; Handelsman DJ; Angus PW; McCaughan GW
    Ann Intern Med; 2006 Feb; 144(4):239-48. PubMed ID: 16490909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
    J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of early treatment with zoledronic acid on prevention of bone loss in patients with acute spinal cord injury: a randomized controlled trial.
    Goenka S; Sethi S; Pandey N; Joshi M; Jindal R
    Spinal Cord; 2018 Dec; 56(12):1207-1211. PubMed ID: 30258212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiretroviral Therapy-Induced Bone Loss Is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-Naive Persons with Human Immunodeficiency Virus Infection: A Phase IIB Trial.
    Ofotokun I; Collins LF; Titanji K; Foster A; Moran CA; Sheth AN; Lahiri CD; Lennox JL; Ward L; Easley KA; Weitzmann MN
    Clin Infect Dis; 2020 Oct; 71(7):1655-1663. PubMed ID: 31621838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
    Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
    Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.
    Miller PD; Pannacciulli N; Brown JP; Czerwinski E; Nedergaard BS; Bolognese MA; Malouf J; Bone HG; Reginster JY; Singer A; Wang C; Wagman RB; Cummings SR
    J Clin Endocrinol Metab; 2016 Aug; 101(8):3163-70. PubMed ID: 27270237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).
    Black DM; Reid IR; Boonen S; Bucci-Rechtweg C; Cauley JA; Cosman F; Cummings SR; Hue TF; Lippuner K; Lakatos P; Leung PC; Man Z; Martinez RL; Tan M; Ruzycky ME; Su G; Eastell R
    J Bone Miner Res; 2012 Feb; 27(2):243-54. PubMed ID: 22161728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of lower extremity bone mineral density 1 year after denosumab is discontinued in persons with subacute spinal cord injury.
    Cirnigliaro CM; La Fountaine MF; Parrott JS; Kirshblum SC; Sauer SJ; Shapses SA; McClure IA; Bauman WA
    Osteoporos Int; 2023 Apr; 34(4):741-748. PubMed ID: 36735054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
    Eastell R; Lang T; Boonen S; Cummings S; Delmas PD; Cauley JA; Horowitz Z; Kerzberg E; Bianchi G; Kendler D; Leung P; Man Z; Mesenbrink P; Eriksen EF; Black DM;
    Osteoporos Int; 2010 Jul; 21(7):1277-85. PubMed ID: 19802508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Reid DM; Devogelaer JP; Saag K; Roux C; Lau CS; Reginster JY; Papanastasiou P; Ferreira A; Hartl F; Fashola T; Mesenbrink P; Sambrook PN;
    Lancet; 2009 Apr; 373(9671):1253-63. PubMed ID: 19362675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT).
    Black DM; Reid IR; Cauley JA; Cosman F; Leung PC; Lakatos P; Lippuner K; Cummings SR; Hue TF; Mukhopadhyay A; Tan M; Aftring RP; Eastell R
    J Bone Miner Res; 2015 May; 30(5):934-44. PubMed ID: 25545380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Percutaneous kyphoplasty combined with zoledronic acid infusion in the treatment of osteoporotic thoracolumbar fractures in the elderly.
    Shi C; Zhang M; Cheng AY; Huang ZF
    Clin Interv Aging; 2018; 13():853-861. PubMed ID: 29765210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zoledronic Acid Treatment After Acute Spinal Cord Injury: Results of a Randomized, Placebo-Controlled Pilot Trial.
    Schnitzer TJ; Kim K; Marks J; Yeasted R; Simonian N; Chen D
    PM R; 2016 Sep; 8(9):833-43. PubMed ID: 26828618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial.
    Billington EO; Horne A; Gamble GD; Maslowski K; House M; Reid IR
    Osteoporos Int; 2017 Jun; 28(6):1867-1874. PubMed ID: 28233020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial.
    Sølling AS; Harsløf T; Langdahl B
    J Bone Miner Res; 2020 Oct; 35(10):1858-1870. PubMed ID: 32459005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
    Saag K; Lindsay R; Kriegman A; Beamer E; Zhou W
    Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
    Boonen S; Black DM; Colón-Emeric CS; Eastell R; Magaziner JS; Eriksen EF; Mesenbrink P; Haentjens P; Lyles KW
    J Am Geriatr Soc; 2010 Feb; 58(2):292-9. PubMed ID: 20070415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial.
    McClung M; Miller P; Recknor C; Mesenbrink P; Bucci-Rechtweg C; Benhamou CL
    Obstet Gynecol; 2009 Nov; 114(5):999-1007. PubMed ID: 20168099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study.
    Shiraki M; Kuroda T; Takeuchi Y; Sugimoto T; Tanaka S; Suzuki H; Hiraishi K; Nakamura T
    Calcif Tissue Int; 2021 Dec; 109(6):666-674. PubMed ID: 34247263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic efficacy of zoledronic acid combined with calcitriol in elderly patients receiving total hip arthroplasty or hemiarthroplasty for osteoporotic femoral neck fracture.
    Zhu K; Zhang J; Zhang C; Zhao Z; Gao J; Li X; Xia X; Xu X; Zhang T; Guan J
    Osteoporos Int; 2021 Mar; 32(3):559-564. PubMed ID: 32989470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.